They accused him of having produced a fraudulent report in November 2018 for Genevrier Laboratories in exchange for a large payment (more than €250,000) in defence of a delisted drug, Chondrosulf.
He was accused of producing a misleading document in November 2018 for Genevrier Laboratories in return for a substantial payment (more than €250,000) to ensure that the discontinued drug Chondrosulf would not be removed from the market.